Chemotherapy Use Will Increase Despite Payment Cuts In 2005, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services expects spending on chemotherapy under Medicare Part B to continue to increase despite reimbursement cuts scheduled for 2005, Administrator Mark McClellan said
You may also be interested in...
CMS Will Release Final 2005 “Average Sales Price” Rule The Week Of Nov. 1
That timeline enables CMS to meet its original goal for publishing the final rule. Any potential fallout from the reg will likely not occur before the Nov. 2 Presidential election.
Medicare “Average Sales Price” Rule Predicts $800 Mil. In Savings For 2005
CMS expects the shift from average wholesale price-based reimbursement to the ASP plus 6% formula to generate savings of $530 mil. to Medicare and $270 mil. to beneficiaries in 2005. The agency expects changes outlined in its proposed rule to bring “transparency and appropriateness” to its payments for Part B drugs.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.